share_log

Panbela Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Panbela Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Panbela Therapeutics | S-1/A：證券上市註冊聲明(修正)
美股SEC公告 ·  08/16 17:28

Moomoo AI 已提取核心訊息

Panbela Therapeutics, Inc. has announced a public offering of 1,460,318 shares of common stock, an equal number of Class G and Class H common warrants, and up to 1,460,318 pre-funded warrants to purchase common stock. The offering also includes up to 5,222,223 shares of common stock underlying the warrants. The company has granted the underwriters an option to purchase additional shares and/or warrants to cover over-allotments. The proceeds from the offering are intended for the continued clinical development of Panbela's product candidates, repayment of debt, and general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Panbela Therapeutics, Inc. has announced a public offering of 1,460,318 shares of common stock, an equal number of Class G and Class H common warrants, and up to 1,460,318 pre-funded warrants to purchase common stock. The offering also includes up to 5,222,223 shares of common stock underlying the warrants. The company has granted the underwriters an option to purchase additional shares and/or warrants to cover over-allotments. The proceeds from the offering are intended for the continued clinical development of Panbela's product candidates, repayment of debt, and general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Panbela Therapeutics，Inc.宣佈進行公開發行1,460,318股普通股，相同數量的G類和H類普通股權證，以及高達1,460,318預融資的購股權證。該發行還包括多達5,222,223股普通股票作爲權證的基礎。公司已授予承銷商購買額外股票和/或權證的選擇權以彌補超額分配。發行所得擬用於Panbela的產品候選繼續進行臨床開發、償還債務和一般性企業用途。發行受市場情況影響，不能保證是否完成發行以及完成發行的時間，或者發行規模或條款的實際情況。
Panbela Therapeutics，Inc.宣佈進行公開發行1,460,318股普通股，相同數量的G類和H類普通股權證，以及高達1,460,318預融資的購股權證。該發行還包括多達5,222,223股普通股票作爲權證的基礎。公司已授予承銷商購買額外股票和/或權證的選擇權以彌補超額分配。發行所得擬用於Panbela的產品候選繼續進行臨床開發、償還債務和一般性企業用途。發行受市場情況影響，不能保證是否完成發行以及完成發行的時間，或者發行規模或條款的實際情況。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間